Pharmacovigilance-related Recommendations for Bravecto (Fluralaner)

New safety warnings for Bravecto have been added following a July 2026 update, mandating immediate label changes.

Source updated: Jul 24, 2026

Primary source: European Medicines Agency (EMA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

Updates to the Summary of Product Characteristics (SPC) and Package Leaflet (PL) for Bravecto, requiring immediate adaptations including specific precautions against hypersensitivity reactions in humans and potential injection site reactions in dogs.

Why it matters

These updated recommendations underscore essential safety measures for veterinarians and inform marketing authorisation holders of the critical need to adapt product information to prevent adverse events.

Action needed

Marketing authorisation holders must update Product Information (SPC and PL) in accordance with CVMP monthly recommendations, and ensure local affiliates are informed of new safety instructions.

Relevant for: Regulatory Intelligence LeadSignal Management LeadLabeling Lead
Processes impacted: LabelingSignal Management
Owner: Regulatory Intelligence Lead
Review cadence: Review in the next regulatory intelligence cycle.

Policy change details

Document type: Guideline
Policy status: revised
Publication date: 2026-04-21
Last updated: 2026-07-24
Policy change: This monthly updated procedural guideline provides CVMP-adopted recommendations for safety label changes for centrally authorized veterinary medicines. The July 2026 update incorporates new safety information and warnings resulting from pharmacovigilance signals and periodic reviews.

Key changes

New safety warnings added for fluralaner (Bravecto) regarding human hypersensitivity and injection site reactions in dogs; updates to product labels (SPC/PL) across several veterinary products based on CVMP outcomes.

Affected workflows

LabelingSignal Management

Responsible groups

Regulatory AffairsPV Operations

PV impact

MAHs for the affected products must update their Product Information (SPC and Package Leaflet) in accordance with the monthly CVMP recommendations. This involves labeling updates and ensuring local affiliates are informed of the new safety instructions.

View regulator source

Source document details

Exact policy details

Monthly Updates: Monthly updates of adopted outcomes of CVMP
Applies to: All centrally authorised veterinary medicinal products
This document is updated monthly with the adopted outcomes of the Committee for Veterinary Medicinal Products (CVMP). · p. 1 · High · Source
Report Submission: Reports should be sent to either the marketing authorisation holder or the national competent authority
Applies to: Veterinary medicinal product reporting
Reporting adverse events is important. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. · p. 6 · High · Source

Workflow rule impacts

Signal ManagementVeterinary Safety Officer

Additional training may be required for veterinarians to address new recommendations

Increased monitoring due to new adverse effects and recommendations

New recommendations require veterinarian caution in administration and consideration of adverse events. · p. 6 · High · Source

Extracted documents

Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2026pdfpdf_text · high · 15 pages

Evidence and confidence

Confidence: highSource updated: Jul 24, 2026

European Medicines Agency (EMA) →Updated July 24, 2026

Full briefing

Practical implication

Marketing authorisation holders must update Product Information (SPC and PL) in accordance with CVMP monthly recommendations, and ensure local affiliates are informed of new safety instructions.

The European Medicines Agency has updated the labeling requirements for centrally authorised veterinary medicinal products, specifically highlighting new safety warnings related to the veterinary product Bravecto, which involves heightened caution for human hypersensitivity and injection site reactions.

What changed: Updates to the Summary of Product Characteristics (SPC) and Package Leaflet (PL) for Bravecto, requiring immediate adaptations including specific precautions against hypersensitivity reactions in humans and potential injection site reactions in dogs.

Why it matters: These updated recommendations underscore essential safety measures for veterinarians and inform marketing authorisation holders of the critical need to adapt product information to prevent adverse events.

Practical implication: Marketing authorisation holders must update Product Information (SPC and PL) in accordance with CVMP monthly recommendations, and ensure local affiliates are informed of new safety instructions.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Labeling #Safety Signals #European Medicines Agency (EMA)#Guideline #revised #policy-change #firecrawl-policy-agent

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead

verifiedRegulatory action: Regulators

Read impact briefarrow_forward

publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead

verifiedRegulatory action: Regulators

Read impact briefarrow_forward

publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead

SOP Impact1 SOPs

Relevant for: PV Quality Lead, Medical Safety Lead

verifiedRegulatory action: Regulators

Read impact briefarrow_forward

publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV

SOP Impact1 SOPs

Relevant for: QPPV, Medical Safety Lead

verifiedRegulatory action: Regulators

Read impact briefarrow_forward